TP53 and cancer: Furthermore, our identification that pathogenic ATM alterations in these atypical cancers are associated with the co-occurrence of alterations in BRCA1 and CHEK2, and mutual exclusivity with TP53, suggests that cancers with a germline pathogenic variant in ATM may depend on specific molecular alterations that confer targetable vulnerabilities.